Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Vivimed Labs Limited ( (IN:VIVIMEDLAB) ) is now available.
Vivimed Labs Limited reported its unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, following approval by its board of directors. The filings, made in compliance with India’s listing regulations, included a limited review report from the statutory auditors, indicating that the company continues to meet its periodic disclosure obligations to stock exchanges and investors.
The latest numbers show a sharp year-on-year decline in quarterly revenue, which fell to about a tenth of the level reported in the same period a year earlier, and the company swung to a net loss for the quarter and nine-month period. The deterioration in performance, driven by lower operating income and persistent cost pressures, underlines continuing operational challenges for Vivimed Labs and may heighten concerns among shareholders and creditors about its near-term earnings trajectory and financial resilience.
More about Vivimed Labs Limited
Vivimed Labs Limited operates in the pharmaceutical and specialty chemicals sector, manufacturing active pharmaceutical ingredients, formulations and related products for domestic and international markets. The company is listed on both BSE and NSE in India, reflecting a diversified shareholder base and regulatory oversight in public markets.
Average Trading Volume: 109,239
Technical Sentiment Signal: Sell
Current Market Cap: 577.9M INR
See more data about VIVIMEDLAB stock on TipRanks’ Stock Analysis page.